CPMP Recommends Stryker OP-1 For European Market Clearance
This article was originally published in The Gray Sheet
Executive Summary
The clinical data supporting Stryker's Osteogenic Protein 1 (OP-1) showed the radiographic healing results of the treatment group to be "slightly inferior" to the autograft control group, CPMP concluded in its recommendation for European market authorization.
You may also be interested in...
Bone Growth Factor Market Offers Attractive Niche For Medtronic
Medtronic/Sofamor Danek expects to submit clinical data supporting a premarket approval application for its InFuse BMP-2 recombinant bone morphogenic protein by mid-year. The company is hoping for expedited FDA review of the product, with a possible rollout by 2002.
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.